In Silico Target Assessment Services

Source: Syngene International Ltd.

Target identification and validation is one of the biggest challenges in the pharmaceutical industry, with many promising treatments failing in the clinic due to efficacy or target-related safety issues. The reason is usually that the underlying hypothesis turns out to be wrong, or there are unwanted consequences of modulating the target. Due diligence around a target early on, can make the difference between success and failure of a program.

In this video, Dr. Kenneth Barr, Syngene's Sr. Vice President of Discovery Services, answers some of the frequently asked questions about Syngene’s in-silico target assessment services. Syngene specialize in in silico-based identification, selection, analysis, and prioritization of potential drug targets by using a combinatorial approach of biology and bioinformatics.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Drug Discovery Online